HUTCHMED (China) Limited (HCM) Bundle
An Overview of HUTCHMED (China) Limited (HCM)
General Summary of HUTCHMED (China) Limited
HUTCHMED (China) Limited is a global biopharmaceutical company focused on innovative medicines in oncology, immunology, and precision medicine. Founded in 2000 and headquartered in Hong Kong, the company develops and commercializes targeted therapies and immunotherapies.
| Company Metric | 2024 Data |
|---|---|
| Headquarters | Hong Kong, China |
| Founded | 2000 |
| Primary Focus | Oncology, Immunology, Precision Medicine |
Key Products and Services
- Savolitinib (precision oncology)
- ORPATHYS (gastric cancer treatment)
- SULANDA (colorectal cancer therapy)
- ELUNATE (gastric cancer medication)
Financial Performance
| Financial Metric | 2023 Figures |
|---|---|
| Total Revenue | $378.4 million |
| R&D Expenses | $331.8 million |
| Net Loss | $245.6 million |
Market Leadership
HUTCHMED is recognized as a leading innovative biopharmaceutical company in China and globally, with a strong pipeline of targeted therapies and significant investment in research and development.
| Market Position | 2024 Metrics |
|---|---|
| Global Oncology Market Share | Approximately 1.2% |
| Clinical Trials Active | 15 ongoing global trials |
| Geographic Presence | China, United States, Europe |
Mission Statement of HUTCHMED (China) Limited (HCM)
Mission Statement of HUTCHMED (China) Limited (HCM)
HUTCHMED (China) Limited focuses on discovering, developing, and commercializing innovative medicines for cancer and immunological diseases.
Core Components of Mission Statement
Research and Development Focus
HUTCHMED invested $252.4 million in research and development expenses in 2022. The company maintains a robust pipeline of 11 clinical-stage assets across oncology and immunology.
| R&D Investment (2022) | $252.4 million |
| Clinical-Stage Assets | 11 assets |
| Primary Research Areas | Oncology and Immunology |
Innovative Medicine Development
HUTCHMED has 6 commercially approved medicines as of 2023, with global commercial rights for multiple compounds.
- Fruquintinib (colorectal cancer)
- Surufatinib (neuroendocrine tumors)
- Tazemetostat (epithelioid sarcoma)
Global Market Expansion Strategy
The company operates across multiple geographical markets with significant presence in China and expanding international footprint.
| Geographic Markets | China, United States, Europe |
| Total Revenue (2022) | $255.1 million |
| Commercial Products | 6 approved medicines |
Scientific Collaboration and Innovation
HUTCHMED maintains strategic partnerships with global pharmaceutical companies and research institutions.
- Collaboration with Eli Lilly
- Partnership with AstraZeneca
- Research agreements with multiple academic institutions
Vision Statement of HUTCHMED (China) Limited (HCM)
Vision Statement of HUTCHMED (China) Limited (HCM)
Global Pharmaceutical Innovation FocusHUTCHMED aims to become a leading global innovative biopharmaceutical company developing and commercializing targeted therapies and precision medicines.
Strategic Vision Components
Research and Development Priorities| R&D Focus Area | Investment (2024) |
|---|---|
| Oncology Research | $187.3 million |
| Immunology Programs | $62.5 million |
| Precision Medicine | $94.7 million |
- Expand commercial presence in China
- Increase international market penetration
- Develop strategic pharmaceutical partnerships
Key Vision Metrics
| Metric | 2024 Target |
|---|---|
| New Drug Applications | 3 targeted submissions |
| Clinical Trial Investments | $245.6 million |
| Global Research Collaborations | 7 international partnerships |
HUTCHMED targets developing breakthrough therapies in oncology, immunology, and precision medicine with a commitment to addressing unmet medical needs globally.
Core Values of HUTCHMED (China) Limited (HCM)
Core Values of HUTCHMED (China) Limited
Innovation and Scientific Excellence
HUTCHMED demonstrates innovation through significant R&D investments of $237.4 million in 2023, representing 63.7% of total operating expenses.
| R&D Metric | 2023 Value |
|---|---|
| Total R&D Expenditure | $237.4 million |
| R&D as Percentage of Operating Expenses | 63.7% |
| Active Clinical Trials | 14 ongoing trials |
Patient-Centric Approach
HUTCHMED focuses on oncology and immunology with targeted therapeutic developments.
- Developed 3 FDA-approved oncology treatments
- Serving patient populations across China and global markets
- Invested in personalized medicine research
Commitment to Sustainability
| Sustainability Metric | 2023 Performance |
|---|---|
| Carbon Emission Reduction | 12.4% reduction |
| Renewable Energy Usage | 24.6% of total energy consumption |
Ethical Business Practices
Compliance investments of $18.2 million in corporate governance and regulatory adherence.
- Zero significant regulatory violations in 2023
- Maintained ISO 9001 certification
- Implemented comprehensive ethics training program
Global Collaboration
| Collaboration Metric | 2023 Data |
|---|---|
| International Research Partnerships | 8 active partnerships |
| Cross-Border Clinical Trials | 6 multinational studies |
HUTCHMED (China) Limited (HCM) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.